Liver Disease and Cirrhosis

Cirrhosis represents the final common pathway of chronic liver disease characterized by progressive hepatic fibrosis culminating in architectural distortion, regenerative nodule formation, and portal hypertension. It affects approximately 2% of the U.S. population with an incidence of 27.4 cases per 100,000 person-years, making it a leading cause of morbidity and mortality globally. The prevalence varies significantly by etiology, with alcohol-related liver disease (ALD) and hepatitis C virus (HCV) infection representing the most common causes in developed nations, while hepatitis B virus (HBV) predominates in endemic regions of Asia and Africa. Cirrhosis is clinically silent in its early stages (compensated cirrhosis) but progresses to decompensated disease characterized by ascites, variceal bleeding, hepatic encephalopathy, and hepatorenal syndrome, with median survival of 2 years without transplantation. Understanding the pathophysiology, diagnosis, and management of cirrhosis is essential for internists, gastroenterologists, and primary care physicians, as early detection and intervention can halt disease progression and prevent life-threatening complications. Cirrhosis also substantially increases hepatocellular carcinoma (HCC) risk across all etiologies, necessitating ongoing surveillance in at-risk populations.

The progression from chronic liver injury to cirrhosis involves complex interplay of hepatocellular necroinflammation, fibrogenesis, and vascular remodeling. Understanding these mechanisms is crucial for comprehending both disease pathology and therapeutic targets.

The fundamental pathological process involves activation of hepatic stellate cells (HSCs), which are liver-resident fibroblasts that remain quiescent in the normal liver but become activated in response to chronic injury. Upon activation by paracrine signals from injured hepatocytes, inflammatory cells, and endothelial cells, HSCs transform into myofibroblast-like cells expressing alpha-smooth muscle actin (α-SMA) and producing excessive extracellular matrix (ECM) proteins, particularly collagen types I and III. This process is mediated by transforming growth factor-beta (TGF-β), the most important profibrogenic cytokine, which acts through TGF-β receptor signaling to promote HSC proliferation, differentiation, and collagen synthesis. Hepatic macrophages (Kupffer cells) amplify this response by releasing additional TGF-β and other inflammatory mediators. Over years to decades, this repetitive cycle of injury-inflammation-fibrosis leads to replacement of normal hepatic architecture with fibrous septa, eventually creating regenerative nodules of hepatocytes surrounded by fibrosis—the histological hallmark of cirrhosis. This architectural remodeling destroys the normal liver microarchitecture, disrupting hepatocyte-sinusoidal endothelial cell contact, impairing nutrient exchange, and creating the substrate for portal hypertension.

Once cirrhosis develops, portal hypertension becomes the central pathophysiological abnormality driving most clinical manifestations. Portal hypertension is defined as elevated portal venous pressure (normal: 5-10 mmHg; pathological: >12 mmHg). The mechanical component involves increased intrahepatic vascular resistance due to architectural distortion, loss of normal sinusoidal compliance, endothelial dysfunction, and capillarization of sinusoids (loss of normal fenestration). Additionally, dynamic components contribute through increased portal blood flow driven by splanchnic vasodilation. The splanchnic vasodilation occurs secondary to production of nitric oxide (NO) and other vasodilators by portal hypertension-activated mesenteric vessels; paradoxically, while improving splanchnic perfusion, this perpetuates the hemodynamic abnormality. The increased portal-collateral flow leads to formation of portosystemic collaterals, including esophageal varices, gastric varices, hemorrhoids, and portal hypertensive gastropathy. Portal hypertension also causes congestion of splanchnic organs, leading to splenomegaly and thrombocytopenia, and contributes to ascites formation through both increased hydrostatic pressure and renal sodium retention.

Progressive cirrhosis causes severe impairment of hepatic synthetic function, manifesting in multiple ways. Hepatocytes lose capacity to produce adequate quantities of serum albumin, leading to hypoalbuminemia with resultant decreased plasma oncotic pressure, which combined with portal hypertension and splanchnic vasodilation contributes to ascites and edema formation. Synthesis of clotting factors (factors II, V, VII, IX, X) progressively declines, prolonging the prothrombin time (PT) and increasing bleeding risk; notably, factor V is most sensitive to hepatic dysfunction and factor VIII is produced by endothelial cells (thus relatively preserved in liver disease), making factor V:factor VIII ratio useful diagnostically. The liver's impaired gluconeogenic capacity, combined with peripheral insulin resistance and decreased hepatic glucose uptake, creates risk for hypoglycemia particularly during fasting or infection. Impaired metabolism of ammonia, a neurotoxic byproduct of protein metabolism normally converted to urea by the liver, leads to hyperammonemia and is central to hepatic encephalopathy pathophysiology. Similarly, impaired clearance of other nitrogenous waste products, manganese, and false neurotransmitters contributes to encephalopathy. The failing liver cannot adequately metabolize estrogen, leading to feminization with spider angiomas, palmar erythema, gynecomastia, and testicular atrophy in men.

A hallmark complication of advanced cirrhosis is progressive renal vasoconstriction leading to hepatorenal syndrome (HRS), a functional renal failure without structural kidney disease. In HRS, systemic vasodilation in cirrhosis triggers compensatory renal vasoconstriction mediated by activation of the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system, and production of vasoconstrictors including norepinephrine, endothelin, and angiotensin II, while decreased renal perfusion pressure and loss of nitric oxide-mediated renal vasodilation further compromise kidney function. This results in avid sodium and water retention, worsening ascites, and ultimately severe reduction in glomerular filtration rate. The development of HRS marks a critical threshold in disease severity with extremely poor prognosis in the absence of transplantation.

Cirrhosis creates profound immunocompromise through multiple mechanisms. The reticuloendothelial system's clearance capacity is overwhelmed, and circulating opsonins are depleted. Gut barrier dysfunction allows bacterial translocation from the intestinal lumen across the epithelium into the portal circulation—a process facilitated by increased intestinal permeability, altered gut microbiota, splanchnic vasodilation with stasis, and elevated intestinal intraluminal pressure. Translocated bacteria activate Kupffer cells and produce inflammatory mediators, contributing to the systemic inflammatory response characteristic of advanced cirrhosis. This explains the increased susceptibility to infections including spontaneous bacterial peritonitis (SBP), urinary tract infections, aspiration pneumonia, and sepsis.

Alcohol represents the most common etiology of cirrhosis in the Western world, accounting for approximately 40% of cases. The risk is dose- and duration-dependent, with daily consumption >40 g in men and >20 g in women conferring increased risk, though substantial individual variation exists due to genetic polymorphisms in alcohol-metabolizing enzymes (aldehyde dehydrogenase, alcohol dehydrogenase) and other factors. Acetaldehyde, the toxic metabolite of ethanol produced by alcohol dehydrogenase, directly injures hepatocytes and promotes oxidative stress through enhanced reactive oxygen species (ROS) production. Alcohol also causes lipopolysaccharide (LPS) translocation from gram-negative gut bacteria, which activates toll-like receptor 4 (TLR4) on Kupffer cells, perpetuating hepatic inflammation. Alcohol-induced steatosis (fat accumulation) precedes fibrosis and increases susceptibility to additional injury. Nutritional deficiency accompanying chronic alcoholism (thiamine, folate, pyridoxine deficiency) worsens hepatic injury. Notably, not all heavy drinkers develop cirrhosis (only 10-20%), suggesting genetic and host factors are critical.

HCV affects approximately 71 million people globally and accounts for 25-30% of cirrhosis cases in developed nations. The virus is transmitted through blood exposure (contaminated blood transfusions before 1992, injection drug use, occupational needlesticks, hemodialysis, occasionally sexual contact). Chronic infection develops in 80% of infected individuals, with progression to cirrhosis occurring in 20-30% of those with chronic infection over 20-30 years; progression is accelerated by concurrent HIV infection, HBV coinfection, male gender, age >40 at infection, and heavy alcohol consumption. HCV damages hepatocytes through both direct viral mechanisms (core and NS5A proteins promote oxidative stress, interfere with apoptosis, and activate innate immunity) and indirect immune-mediated injury. Direct-acting antiviral (DAA) therapy now achieves sustained virological response (SVR) rates >95%, effectively preventing cirrhosis development and even reversing early fibrosis.

HBV causes chronic infection in 5-10% of immunocompetent adults and >90% of infants exposed perinatally. Globally, HBV accounts for 50% of cirrhosis cases and is the leading etiology in endemic regions of Asia-Pacific and sub-Saharan Africa. The risk of progression to cirrhosis varies by HBeAg status, viral load, and degree of hepatic inflammation; patients with HBeAg-positive disease and high viral loads (>10^7 copies/mL) have higher cirrhosis risk. HBV integrates into the hepatocyte genome, and viral proteins (particularly hepatitis B X protein [HBx]) promote oxidative stress, impair apoptosis, and activate oncogenic pathways. Hepatitis B surface antigen (HBsAg) persistence for >6 months defines chronic infection. Antiviral therapy with nucleos(t)ide analogues (entecavir, tenofovir) effectively suppresses viral replication and can prevent cirrhosis progression or even promote fibrosis regression in some patients.

HDV is a defective virus requiring HBV for replication; it can coinfect simultaneously with HBV or superinfect chronic HBV carriers. HDV significantly accelerates progression to cirrhosis, with 70-80% of HDV-coinfected patients developing cirrhosis within 5-10 years. HDV is transmitted through blood exposure similar to HBV and is endemic in certain regions (Mediterranean basin, parts of Africa, South America). HBV vaccination prevents both HBV and HDV infection; those with chronic HBV should be monitored for anti-HDV antibodies.

NAFLD, characterized by hepatic steatosis in the absence of significant alcohol consumption, affects 25-30% of the general population and is emerging as the leading cause of cirrhosis in developed nations. NASH (nonalcoholic steatohepatitis) represents the subset with hepatic inflammation and hepatocyte injury and carries risk for progression; approximately 20% of NASH patients develop cirrhosis over 10-15 years. NAFLD/NASH is strongly associated with metabolic syndrome components: obesity (particularly visceral adiposity), type 2 diabetes mellitus, insulin resistance, dyslipidemia, and hypertension. The pathophysiology involves increased hepatic uptake and synthesis of free fatty acids, impaired fatty acid oxidation, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress, and lipotoxicity. Lipopolysaccharide translocation from dysbiotic gut microbiota and activation of pattern recognition receptors (TLRs) amplify inflammation. Unfortunately, no FDA-approved pharmacotherapies exist for NAFLD/NASH; management focuses on metabolic risk factor modification, weight loss (≥10% body weight loss improves histology), diabetes control, and treatment of dyslipidemia.

AIH is a chronic inflammatory condition of unknown trigger characterized by genetic predisposition (association with HLA-DR3 and HLA-DR4 alleles), autoantibodies (antinuclear antibodies [ANA], anti-smooth muscle antibodies [SMA], anti-liver kidney microsomal antibodies [anti-LKM]), and hypergammaglobulinemia. It predominantly affects women (70% of cases) with peak incidence in young adults or older adults. Progressive necroinflammatory activity leads to cirrhosis in 30-40% if untreated. Immunosuppressive therapy with corticosteroids (prednisone) and azathioprine or 6-mercaptopurine effectively induces remission and halts disease progression.

PBC is a cholestatic liver disease of unknown autoimmune etiology characterized by progressive destruction of intrahepatic bile ducts, predominantly affecting middle-aged women. Antimitochondrial antibodies (AMA) targeting pyruvate dehydrogenase complex (PDC-E2) are highly specific. Bile duct loss and cholestasis trigger hepatic fibrosis; cirrhosis develops in 20-40% of patients over 10-20 years. Ursodeoxycholic acid (UDCA) is first-line therapy and improves transplant-free survival; obeticholic acid (FXR agonist) is second-line for inadequate UDCA response.

PSC involves progressive fibroinflammatory stricturing of intra- and extrahepatic bile ducts of unknown etiology, strongly associated with inflammatory bowel disease (IBD) in 80% of cases. It predominantly affects men (65% of cases) with peak incidence in 30s-40s. Bile duct strictures cause cholestasis and recurrent bacterial cholangitis, accelerating fibrosis; 50% of patients develop cirrhosis within 12 years. Ursodeoxycholic acid is used, though evidence for benefit is mixed. PSC significantly increases risk of cholangiocarcinoma and requires ongoing surveillance. Liver transplantation is definitive therapy for advanced disease.

Hereditary hemochromatosis (HH), most commonly caused by HFE gene mutations (C282Y homozygosity in 80% of cases), leads to excessive intestinal iron absorption. Iron accumulates in hepatocytes, hepatic macrophages, and other organs, promoting free radical-mediated oxidative stress via Fenton chemistry. This causes hepatocyte necrosis, fibrosis, and cirrhosis, particularly if cirrhosis develops prior to iron overload treatment. Secondary hemochromatosis occurs with chronic transfusions or hemolytic anemias. Phlebotomy effectively removes excess iron and prevents cirrhosis development or halts progression if caught early; deferasirox (iron chelator) is alternative. HCC risk remains elevated even after iron reduction if cirrhosis is established.

This autosomal recessive disorder of copper metabolism caused by ATP7B gene mutations results in impaired hepatic copper excretion into bile. Copper accumulates in liver, brain (particularly basal ganglia), cornea, and kidneys, causing hepatic inflammation, fibrosis, and potential cirrhosis; neuropsychiatric manifestations are prominent including tremor, rigidity, personality changes, and psychosis. Kayser-Fleischer rings (copper deposition in Descemet membrane) are pathognomonic. Disease presentation ranges from acute liver failure in adolescents to chronic hepatitis with cirrhosis. Penicillamine and trientine are copper chelators; zinc supplementation reduces intestinal copper absorption. Early diagnosis and treatment prevent progression to cirrhosis.

AAT deficiency, caused by SERPINA1 gene mutations, is most common genetic cause of cirrhosis in children and young adults in developed nations. The Z allele (Glu342Lys) causes protein misfolding and polymerization in hepatocytes. Serum AAT <57 μmol/L (11 mg/dL)

The stem is typically a middle-aged patient with years of heavy alcohol use, a remote blood transfusion or injection drug use (HCV), or obesity with type 2 diabetes (NASH), presenting with abdominal distension or confusion.

Cirrhosis is usually a composite clinical, laboratory, imaging, and elastography diagnosis; biopsy is reserved for uncertainty.

Confirmatory test: liver biopsy (percutaneous, or transjugular when ascites or coagulopathy is present) remains the histologic gold standard, showing regenerative nodules encircled by fibrous septa.

Diagnostic paracentesis is mandatory for new ascites (AASLD): SAAG ≥1.1 g/dL indicates portal hypertension, and an ascitic total protein <2.5 g/dL separates cirrhosis from cardiac ascites. Ascitic PMN ≥250/mm³ diagnoses SBP.

Severity scoring: Child–Turcotte–Pugh (bilirubin, albumin, INR, ascites, encephalopathy) and MELD 3.0, used by UNOS for transplant allocation.

Immediate stabilization (variceal hemorrhage): two large-bore IVs, restrictive transfusion to a hemoglobin threshold near 7 g/dL (over-transfusion raises portal pressure and rebleeding risk), a splanchnic vasoconstrictor (octreotide infusion), and prophylactic antibiotics — ceftriaxone — which reduce infection and mortality in any cirrhotic with GI bleeding. Endoscopy with band ligation within about 12 hours; balloon tamponade or an esophageal stent bridges refractory bleeding to early TIPS, which Baveno VII endorses in high-risk patients. This mirrors AASLD and ACG guidance.

Definitive management: liver transplantation, prioritized by MELD 3.0.

Contraindicated/avoid: NSAIDs and aminoglycosides (precipitate AKI and HRS), benzodiazepines and opioids (precipitate encephalopathy), prophylactic FFP for an elevated INR alone, and protein restriction in encephalopathy. Vaccinate against hepatitis A/B, influenza, and pneumococcus.